Subject(s)
Biomarkers, Tumor/analysis , Epigenesis, Genetic , Nerve Sheath Neoplasms/diagnosis , Neurofibroma/diagnosis , Neurofibromatosis 1/complications , Aged , Biomarkers, Tumor/genetics , DNA Methylation , Diagnosis, Differential , Enhancer of Zeste Homolog 2 Protein/analysis , Enhancer of Zeste Homolog 2 Protein/genetics , Female , Histones/analysis , Histones/genetics , Humans , Immunohistochemistry , Nerve Sheath Neoplasms/genetics , Nerve Sheath Neoplasms/pathology , Neurofibroma/genetics , Neurofibroma/pathology , Neurofibromatosis 1/genetics , Neurofibromatosis 1/pathology , Skin/pathologySubject(s)
Breast , Choristoma/pathology , Hyperhidrosis/etiology , Pregnancy Outcome , Subcutaneous Tissue/pathology , Adult , Axilla , Biopsy, Needle , Choristoma/complications , Female , Humans , Hyperhidrosis/pathology , Immunohistochemistry , Pregnancy , Pregnancy Complications , Pregnancy Trimester, Third , Risk Assessment , Watchful WaitingSubject(s)
Antineoplastic Agents, Immunological/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colitis/drug therapy , Diarrhea/drug therapy , Infliximab/therapeutic use , Aged , Biopsy , Colitis/chemically induced , Colitis/diagnosis , Colitis/pathology , Colon/diagnostic imaging , Colon/drug effects , Colon/pathology , Colonoscopy , Diarrhea/chemically induced , Diarrhea/diagnosis , Diarrhea/pathology , Female , Humans , Ipilimumab/adverse effects , Melanoma/drug therapy , Melanoma/pathology , Nivolumab/adverse effects , Severity of Illness Index , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Tomography, X-Ray ComputedSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Interferon alpha-2/therapeutic use , Interferon-alpha/therapeutic use , Interferon-beta/therapeutic use , Melanoma/secondary , Polyethylene Glycols/therapeutic use , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Brain Neoplasms/secondary , Chemotherapy, Adjuvant , Duodenal Neoplasms/secondary , Fatal Outcome , Humans , Liver Neoplasms/secondary , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Recombinant Proteins/therapeutic use , Melanoma, Cutaneous MalignantABSTRACT
We report a case of bilateral annular breast keloids in a 72-year-old woman who had been suffering from bilateral breast cancers. Histopathologically, the keloids showed unique distribution of α-SMA+, CD34- myofibroblasts and α-SMA-, CD34+ fibroblasts depending on the region. High serum levels of tumor growth factor-ß were detected at 6 months after the development of the breast keloids, but not at 10 months. CD163-positive cells were abundantly detected in the skin of the elevated portion of the keloids. In contrast, these cells were considerably less numerous in the skin of the central healing portion compared with the skin of the elevated expanding portion. One interesting idea based on these results is that high levels of tumor growth factor-ß released from CD163-positive cells played a crucial role in the formation of breast keloids through active induction of fibroblast differentiation into myofibroblasts. The present case strongly supports the previously proposed idea that keloids can form as a paraneoplastic phenomenon in breast cancer patients with keloid constitution.
Subject(s)
Breast Neoplasms/complications , Keloid/etiology , Aged , Female , Humans , Keloid/blood , Keloid/pathology , Lymphotoxin-alpha/blood , Skin/pathologySubject(s)
Histiocytosis, Sinus/complications , Uveitis/complications , Age of Onset , Female , Humans , MaleABSTRACT
Thrombocytopenia is often caused by myelosuppression during chemotherapy. However, when platelet transfusions are required, pathological conditions such as idiopathic thrombocytopenic purpura(ITP)and thrombotic thrombocytopenic purpura( TTP)also occur. We report a case of Merkel cell carcinoma complicated with severe thrombocytopenia treated with carboplatin/etoposide regimen after surgery. The patient's platelet count did not increase in spite of platelet transfusions. However, the platelet count increased after steroid treatment was chosen under the diagnosis of ITP. Subsequent examinations revealed that the patient had HLA antibody, which caused the platelet transfusion refractoriness. When the platelet count does not increase in spite of platelet transfusions during chemotherapy, the possibility that the platelet transfusion refractoriness is due to the presence of HLA antibody should be considered.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/adverse effects , Carcinoma, Merkel Cell/drug therapy , Etoposide/adverse effects , Skin Neoplasms/drug therapy , Thrombocytopenia/therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Carcinoma, Merkel Cell/surgery , Etoposide/administration & dosage , Female , HLA Antigens/immunology , Humans , Platelet Transfusion , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Thrombocytopenia/chemically inducedABSTRACT
Solitary venous malformation (VM) of the skin, previously known as cavernous hemangioma, is frequently observed in the dermatological field, but multiple acquired VM are rare. We present a case of multiple VM of the skin associated with multiple cerebral cavernous malformations (CCM) in a 70-year-old Japanese woman. In addition, we summarize seven reported similar cases, including the present case. That some reports have described concomitant VM of the skin and CCM, together with the present case, suggests a tight relationship or a common pathogenetic pathway between these two diseases.
Subject(s)
Brain Neoplasms/diagnosis , Hemangioma, Cavernous, Central Nervous System/diagnosis , Rare Diseases/diagnosis , Skin Neoplasms/diagnosis , Aged , Brain/diagnostic imaging , Brain Neoplasms/complications , Brain Neoplasms/etiology , Brain Neoplasms/pathology , Dermatologic Surgical Procedures , Female , Hemangioma, Cavernous, Central Nervous System/complications , Hemangioma, Cavernous, Central Nervous System/etiology , Hemangioma, Cavernous, Central Nervous System/pathology , Humans , Hypesthesia/etiology , Magnetic Resonance Imaging , Pain/etiology , Rare Diseases/complications , Rare Diseases/etiology , Rare Diseases/pathology , Skin/diagnostic imaging , Skin/pathology , Skin Neoplasms/etiology , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Subcutaneous Tissue/abnormalities , Subcutaneous Tissue/pathology , Subcutaneous Tissue/surgery , Tomography, X-Ray Computed , Torso/diagnostic imaging , Torso/pathology , Torso/surgery , Upper Extremity/diagnostic imaging , Upper Extremity/pathology , Upper Extremity/surgeryABSTRACT
Concomitant confluent and reticulated papillomatosis (CRP) and acanthosis nigricans (AN) is rare. We present a case of concomitant CRP and obesity-associated AN in a 12-year-old obese Japanese girl. Curiously, oral minocycline therapy, which has been shown to be effective for CRP, was effective against both CRP and AN. Possible mechanisms by which minocycline could have improved skin lesions of CRP and obesity-associated AN are discussed. In addition, reports of concomitant CRP and obesity-associated AN are reviewed. CRP and obesity-associated AN share common clinicopathological features and some reports have described concomitant CRP and obesity-associated AN. Together with the observation that skin lesions of CRP and obesity-associated AN in the present case responded to oral minocycline therapy, these facts suggest a tight relationship or a common pathogenetic pathway between these pathologies.
Subject(s)
Acanthosis Nigricans/drug therapy , Insulin Resistance , Obesity/drug therapy , Papilloma/drug therapy , Rare Diseases/drug therapy , Skin Neoplasms/drug therapy , Acanthosis Nigricans/blood , Acanthosis Nigricans/complications , Alkaline Phosphatase/blood , Anti-Bacterial Agents/therapeutic use , Biopsy , Blood Glucose/analysis , C-Peptide/blood , Child , Female , Humans , Minocycline/therapeutic use , Obesity/blood , Obesity/complications , Papilloma/blood , Papilloma/pathology , Rare Diseases/blood , Rare Diseases/complications , Rare Diseases/pathology , Skin/pathology , Skin Neoplasms/blood , Skin Neoplasms/pathology , Syndrome , Treatment OutcomeSubject(s)
Coloring Agents/adverse effects , Eyebrows , Immunosuppressive Agents/administration & dosage , Steroids/administration & dosage , Tacrolimus/administration & dosage , Tattooing/adverse effects , Administration, Topical , Adult , Drug Administration Schedule , Female , Granuloma, Foreign-Body/etiology , Humans , Treatment OutcomeSubject(s)
Bone Marrow/metabolism , Bone Marrow/pathology , Hypercalcemia/complications , Melanoma/metabolism , Melanoma/pathology , Neural Cell Adhesion Molecules/metabolism , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Adult , Fatal Outcome , Humans , Male , Melanoma, Cutaneous MalignantSubject(s)
Edema/etiology , Eyelid Diseases/etiology , Mixed Connective Tissue Disease/complications , Skin Diseases/etiology , Adult , Glucocorticoids/therapeutic use , Humans , Male , Mixed Connective Tissue Disease/diagnosis , Mixed Connective Tissue Disease/drug therapy , Prednisolone/therapeutic use , Raynaud Disease/etiology , Skin Diseases/pathologySubject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Indoles/therapeutic use , Melanoma/drug therapy , Skin Neoplasms/pathology , Sulfonamides/therapeutic use , Vitiligo/chemically induced , Adult , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Gastrointestinal Neoplasms/secondary , Gastrointestinal Neoplasms/therapy , Humans , Indoles/adverse effects , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Male , Melanoma/radiotherapy , Melanoma/secondary , Nivolumab , Skin Neoplasms/therapy , Sulfonamides/adverse effects , VemurafenibSubject(s)
Facial Dermatoses/drug therapy , Immunosuppressive Agents/therapeutic use , Lichen Sclerosus et Atrophicus/drug therapy , Tacrolimus/therapeutic use , Telangiectasis/drug therapy , Administration, Cutaneous , Aged , Cheek , Female , Humans , Immunosuppressive Agents/administration & dosage , Lichen Sclerosus et Atrophicus/complications , Tacrolimus/administration & dosage , Telangiectasis/complicationsABSTRACT
Ultraviolet (UV) B is a major factor in melanomagenesis. This fact is linked to the resistance of melanocytes to UVB-induced apoptosis. In this study, we characterized the involvement of Mcl-1L in the regulation of UVB-induced apoptosis in melanocytes and in melanoma cells. In melanocytes, apoptosis was not evident at 24 h after UVB irradiation. The Mcl-1L expression increased after UVB irradiation, and the high Mcl-1L expression continued for at least 24 h. This UVB-dependent increase in Mcl-1L was mediated by the MEK-ERK-pS-STAT3 (STAT3 phosphorylated at Ser727) pathway. The Ser727 phosphorylation facilitated nuclear localization of STAT3. In melanoma cells, the expression levels of Mcl-1L varied depending on the cell line. WM39 melanoma cells expressed high levels of Mcl-1L via the MEK-ERK-pS-STAT3 pathway and were resistant to UVB-induced apoptosis without up-regulation of Mcl-1L. In melanocytes and in WM39 cells, transfection with Mcl-1 siRNA promoted UVB-induced apoptosis. Immunohistochemical studies showed that melanoma cells in in situ lesions expressed high amounts of Mcl-1L. These results indicate that the high expression of Mcl-1L mediated by the MEK-ERK-pS-STAT3 pathway protects melanocytes and melanoma cells from UVB-induced apoptosis.